PROCEPT BioRoboticsPRCT +4.95%70 Net Current Asset Value is $5.07 as of Mar. 2026, which is 47% below its 10-year median of 9.53. GuruFocus rates PRCT with a GF Score™ of 70/100 and a GF Value™ of $92.12 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 566 Medical Devices & Instruments companies, PROCEPT BioRobotics ranks better than 55.48% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
PROCEPT BioRobotics's net current asset value per share for the quarter that ended in Mar. 2026 was $5.07.
The historical rank and industry rank for PROCEPT BioRobotics's Net Current Asset Value or its related term are showing as below:
PRCT'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 4.26 Med: 9.53 Max: 22.01
Current: 4.45
During the past 7 years, the highest Price-to-Net-Current-Asset-Value Ratio of PROCEPT BioRobotics was 22.01. The lowest was 4.26. And the median was 9.53.
PRCT's Price-to-Net-Current-Asset-Value is ranked better than 55.48% of 566
companies
in the Medical Devices & Instruments industry
Industry Median: 4.89
vs PRCT: 4.45
PROCEPT BioRobotics (NAS:PRCT) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
PROCEPT BioRobotics Net Current Asset Value Related Terms
PROCEPT BioRobotics Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for PROCEPT BioRobotics's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PRCT vs ALMR, AHCO, ENOV: Net Current Asset Value Comparison
For the Medical Devices subindustry, PROCEPT BioRobotics's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PROCEPT BioRobotics Price-to-Net-Current-Asset-Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, PROCEPT BioRobotics's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where PROCEPT BioRobotics's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of $5.07 mean?
PROCEPT BioRobotics (PRCT) has a Net Current Asset Value of $5.07 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on PROCEPT BioRobotics and its competitors. This is 47% below median its historical median of 9.53. Over the past decade, PROCEPT BioRobotics' Net Current Asset Value has ranged from 4.26 to 22.01. According to the industry distribution chart, PROCEPT BioRobotics ranks #252 out of 566 companies in the Medical Devices & Instruments industry, placing it in the top 44.5%.
Is PROCEPT BioRobotics' Net Current Asset Value too high?
PROCEPT BioRobotics' current Net Current Asset Value of $5.07 is 47% below median its 10-year median of 9.53. Over the past 10 years, this metric has ranged from a low of 4.26 to a high of 22.01. The Medical Devices & Instruments industry median Net Current Asset Value is 4.89. PROCEPT BioRobotics' value of $5.07 is 3.7% above this industry median. Based on the distribution chart, PROCEPT BioRobotics ranks #252 out of 566 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, PROCEPT BioRobotics has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PROCEPT BioRobotics' Net Current Asset Value compare to ALMR and AHCO?
According to the Medical Devices & Instruments industry distribution chart, PROCEPT BioRobotics ranks #252 out of 566 companies for Net Current Asset Value. This puts PROCEPT BioRobotics in the upper half of its industry. The industry median Net Current Asset Value is 4.89. PROCEPT BioRobotics' value of $5.07 is 3.7% above this benchmark. Historically, PROCEPT BioRobotics' own Net Current Asset Value has ranged from 4.26 to 22.01 over the past decade. While the company's 10-year median is 9.53 vs. the industry median of 4.89, PROCEPT BioRobotics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Medical Devices & Instruments company?
The median Net Current Asset Value among Medical Devices & Instruments companies is 4.89, based on 566 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PROCEPT BioRobotics's current Net Current Asset Value of $5.07 is 3.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on PROCEPT BioRobotics and its competitors. For the Medical Devices & Instruments industry, the median Net Current Asset Value is 4.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PROCEPT BioRobotics's current Net Current Asset Value is $5.07, which is 47% below median its own 10-year median of 9.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PROCEPT BioRobotics stock overvalued right now?
Based on GuruFocus' analysis, PROCEPT BioRobotics (PRCT) is currently considered Significantly Undervalued. The stock's GF Value™ is $92.12, compared to a current price of $22.56 — trading 75.5% below its estimated fair value. The current Net Current Asset Value is $5.07, which is 47% below median its 10-year median of 9.53 and 3.7% above the Medical Devices & Instruments industry median of 4.89. PROCEPT BioRobotics' overall GF Score™ is 70/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For PROCEPT BioRobotics (PRCT), the current Net Current Asset Value is $5.07 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PROCEPT BioRobotics (PRCT) Overvalued in 2026?
Based on GuruFocus' analysis, PROCEPT BioRobotics stock appears to be undervalued.
The current stock price of $22.56 is trading 75.5% below its estimated GF Value™ of $92.12.
GuruFocus considers PROCEPT BioRobotics to be Significantly Undervalued.
Key valuation signals for PRCT:
Net Current Asset Value: $5.07 (47% below median its 10-year median of 9.53)
GF Value™: $92.12 vs. price of $22.56 (75.5% below fair value)
Industry Position: 3.7% above the Medical Devices & Instruments median (#252 of 566)
No single metric tells the full story. See the PRCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
70GF Score
Get the complete analysis for PRCT
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRCT has been successfully added to your 
